DIVISLAB

Divis Laboratories Ltd.

NSE: DIVISLAB

BSE: 532488

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

8,597.00+27.0 (+0.32%)

21 Aug, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

95.0 / 100

Value Score

8.5 / 100

Price Momentum Score

92.7 / 100

QVM Score

80.5 / 100

Key Metrics

Market Cap

2,28,224 Cr

P/E (TTM)

78.03

P/B

13.62

P/S (TTM)

20.32

EV/EBITDA

57.40

CAPE (5Y)

99.32

ROE (TTM)

16.19

ROCE (TTM)

18.76

ROA (TTM)

13.89

Avg 3Y ROE

14.56

Earnings 3Y CAGR

25.57

Sales 3Y CAGR

15.49

Sales 5Y CAGR

9.30

Debt/Equity

0.00

Consensus TP

7959.00

Strong Buy %

22.22

Promoter Holding

51.88

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Divis Laboratories Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Strong price momentum

Price Momentum score of 92.7 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term

What is Price Momentum score?

92.7 / 100

Analysts have been raising forward EPS estimates

Analyst EPS estimate (consensus) for forward EPS has increased by 5.76% in the last 3 months, indicating earnings momentum

What is Earnings upgrade (3M)?

High and stable ROE

The company reported strong ROE of 16.19% for 12-month ended 30 Jun 2026 and ROE improved marginally by 83 bps from 1 year ago

What is ROE (FY)?

High and improving operating margin

The company reported strong operating margin of 31.08% for 12-month ended 30 Jun 2026 and operating margin improved by 354 bps from 1 year ago

What is Operating profit margin?

Moderate revenue growth and above median growth of industry

The company delivered moderate revenue growth of 16.35% for 12-month ended 30 Jun 2026 and the growth was 5.76 percentage points higher than median growth of industry

What is Sales growth (1Y)?

Median: 10.59

Value 16.35

-99.6111701.8

Strong EPS growth and above median growth of industry

The company delivered strong EPS growth of 26.81% for 12-month ended 30 Jun 2026 and the growth was 19.61 percentage points higher than median growth of industry

What is EPS growth (1Y)?

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.0 as on 30 Jun 2026 and Debt to Equity remained same in the last 1 year

What is Debt to Equity?

Consistently pays dividend

The company has not missed dividend payments once in the last 5 financial years

What is Dividend streak?

Company is net cash

The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet

What is Net Debt ?

Negative

Expensive and at a premium to industry median P/E

PE TTM of 78.03 indicates that the stock is expensive on a standalone basis and is at a 154.17% premium to industry median P/E

What is P/E Ratio?

Median: 30.7

Value 78.03

-0.84752.64

Low dividend yield

The company has a low dividend yield of 0.35%

What is Dividend yield?

Neutral

Company's earnings are of moderate quality

Earnings quality score of 67.4 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

67.4 / 100

Financial Snapshot

See detailed analysis

Multi-year trends for Divis Laboratories Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Divis Laboratories Ltd. Shareholding Pattern

Quarterly breakdown of Divis Laboratories Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Promoter	51.97	51.97	51.96	51.95	51.95	51.95	51.95	51.95	51.94	51.94	51.94	51.94	51.94	51.93	51.93	51.92	51.92	51.90	51.89	51.89	51.89	51.89	51.89	51.88	51.88	51.88
Indian Promoter	51.97	51.97	51.96	51.95	51.95	51.95	51.95	51.95	51.94	51.94	51.94	51.94	51.94	51.93	51.93	51.92	51.92	51.90	51.89	51.89	51.89	51.89	51.89	51.88	51.88	51.88
Foreign Promoter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Institutions	34.67	34.97	37.08	37.23	36.61	37.16	37.06	37.03	36.77	36.51	36.18	35.82	35.74	35.93	36.34	36.74	36.89	37.93	38.31	38.53	38.72	38.79	39.15	39.35	39.51	39.58
Mutual Funds / UTI	14.67	15.57	14.84	13.19	12.59	12.61	12.63	13.35	13.68	13.85	13.62	12.68	13.15	13.20	13.62	13.72	14.28	13.10	11.92	11.89	12.83	13.31	13.99	13.73	13.42	13.87
FI/Bank/Insurance	0.93	1.23	0.01	0.00	0.05	0.00	0.00	0.05	0.05	0.09	5.92	6.88	6.89	7.03	7.35	7.43	7.24	8.03	8.56	7.73	7.30	5.13	5.17	4.96	4.82	4.49
Govt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	19.08	18.17	18.28	20.37	19.87	20.60	20.70	19.30	18.45	16.52	15.40	15.15	14.67	14.69	14.60	14.85	14.68	16.16	17.25	17.98	18.01	19.74	19.39	20.08	20.29	20.19
Other Institutions	0.00	0.00	3.96	3.67	4.10	3.96	7.05	8.29	8.80	6.05	1.24	1.11	1.03	1.02	0.77	0.73	0.68	0.63	0.59	0.91	0.59	0.61	0.61	0.58	0.98	1.02
Non-Institution	13.35	13.07	10.96	10.83	11.45	10.89	11.00	11.02	11.28	11.56	11.87	12.24	12.31	12.14	11.73	11.34	11.19	10.18	9.80	9.59	9.39	9.32	8.96	8.76	8.60	8.54
Bodies Corporate	2.03	1.37	1.41	1.41	1.36	1.39	1.39	1.32	1.33	1.35	1.39	1.41	1.38	1.37	1.45	1.36	1.36	1.33	1.32	1.27	1.24	1.26	1.20	1.20	1.19	1.19
Others (incl. Retail) No. of shareholders	11.32 93,887	11.70 1,17,709	9.55 1,39,804	9.42 1,55,137	10.09 2,05,471	9.50 1,91,120	9.61 2,20,450	9.70 2,71,338	9.95 3,06,157	10.21 3,43,582	10.48 3,75,924	10.83 4,11,547	10.93 4,30,345	10.77 3,98,948	10.28 3,70,731	9.98 3,51,450	9.83 3,44,685	8.85 2,95,590	8.48 2,76,235	8.32 2,77,851	8.15 2,64,888	8.06 2,56,888	7.76 2,47,042	7.56 2,31,558	7.41 2,25,807	7.35 2,24,059

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

#	Index	Weight	Rank
1	Nifty Pharma	10.36%	2 / 20
2	Nifty Healthcare	8.91%	2 / 20
3	Nifty Next 50	4.04%	1 / 50
4	Nifty100 Quality 30	3.43%	14 / 30
5	Nifty 100 Equal Weight	1.16%	4 / 100
6	Nifty 100	0.74%	37 / 100
7	Nifty 500	0.51%	38 / 499
8	Nifty Total Market	0.49%	38 / 749
9	NIFTY Large Midcap 250	0.37%	83 / 250

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Divis Laboratories Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
Nimmagadda Venkata Anirudh Designated Person	June-2026	Market Sale (Disposal) 6th Jun 2026	0.08 %	₹ 6,687.34	15.80 k	₹ 10.57 cr
A. Lakshmi Immediate Relative	March-2026	Market Sale (Disposal) 31st Mar 2026	0.00 %	₹ 6,413.00	500.00	₹ 32.06 lac
K. Sridevi Immediate Relative	July-2025	Market Sale (Disposal) 2nd Jul 2025	0.00 %	₹ 6,726.33	150.00	₹ 10.09 lac
K. Sridevi Immediate Relative	June-2025	Market Sale (Disposal) 13th Jun 2025	0.00 %	₹ 6,741.85	400.00	₹ 26.97 lac
Y. Vamsi Krishna Immediate Relative	June-2025	Market Sale (Disposal) 11th Jun 2025	0.00 %	₹ 6,678.00	200.00	₹ 13.36 lac
Ch. Venu Designated Person	May-2025	Market Sale (Disposal) 28th May 2025	0.00 %	₹ 6,745.00	150.00	₹ 10.12 lac
G.Kelitha Immediate Relative	May-2025	Market Sale (Disposal) 28th May 2025	0.00 %	₹ 6,993.33	150.00	₹ 10.49 lac
Divi Madhusudana Rao Promoter Group	May-2025	Market Sale (Disposal) 27th May 2025	0.07 %	₹ 6,642.51	10.00 k	₹ 6.64 cr
K. Sridevi Immediate Relative	May-2025	Market Sale (Disposal) 27th May 2025	0.00 %	₹ 6,734.58	600.00	₹ 40.41 lac
S Rajani Immediate Relative	May-2025	Market Sale (Disposal) 27th May 2025	0.01 %	₹ 6,746.00	100.00	₹ 6.75 lac

…

Corporate Actions

History of Divis Laboratories Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Dividend₹ 30/share
Record date: 24th Jul 2026Ex-date: 24th Jul 2026
Announced on: 23rd May 2026
Dividend₹ 30/share
Record date: 25th Jul 2025Ex-date: 25th Jul 2025
Announced on: 17th May 2025
Dividend₹ 30/share
Record date: 2nd Aug 2024Ex-date: 2nd Aug 2024
Announced on: 25th May 2024
Dividend₹ 30/share
Record date: 11th Aug 2023Ex-date: 11th Aug 2023
Announced on: 20th May 2023
Dividend₹ 30/share
Record date: 12th Aug 2022Ex-date: 11th Aug 2022
Announced on: 23rd May 2022

Company Profile

Overview of Divis Laboratories Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Divis Laboratories Limited is an India-based company, which is engaged in pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients with predominance in exports. The Companys products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromet...

Key personnel

Mr. Venkatesa Perumallu Pasumarthy

Chief Financial Officer

Mr. Meka Satish Choudhury

Compliance Officer, Company Secretary

Dr. Ramesh B. Venkata NimmagaddaD

Non-Executive Independent Chairman of the Board

Dr. Kiran Satchandra Divi, Ph.D.D

Chief Executive Officer, Whole-Time Director

Dr. Murali Krishna Pr Divi, Ph.D.D

Managing Director, Executive Director

Ms. Nilima Prasad DiviD

Whole-Time Director - (Commercial)

Shri. Nimmagadda Venkata RamanaD

Executive Director

Dr. Sureddy Devendra RaoD

Whole-Time Director - (Manufacturing)

View all

Incorporated on

12 Oct 1990

Last Annual

31 Mar 2026

Last Interim

30 Jun 2026

No. of Employees

19,300

IPO date

12 Mar 2003

Free Float

12,74,46,302

Website

https://www.divislabs.com/

Phone no.

+914023786300

Address

1-72/23(P)/Divis/303,, Divi Towers, Cyber Hills, Gachibowli,, HYDERABAD, 500032, India

Frequently Asked Questions

What is the current share price of Divis Laboratories Ltd.?

The current share price of Divis Laboratories Ltd. is ₹ 8,597.00 as of 21 Aug 2026.

What is the market capitalisation of Divis Laboratories Ltd.?

The market capitalisation of Divis Laboratories Ltd. stands at ₹ 2,28,224.00 Cr.

What is the PE ratio of Divis Laboratories Ltd.?

The Price-to-Earnings (PE) ratio of Divis Laboratories Ltd. is 78.03 as of the latest trailing twelve months data.

What is the ROE and ROCE of Divis Laboratories Ltd.?

Divis Laboratories Ltd. has a Return on Equity (ROE) of 16.19% and a Return on Capital Employed (ROCE) of 18.76% as per the latest financial reports.

What is the 52-week high and low of Divis Laboratories Ltd.?

The 52-week high of Divis Laboratories Ltd. is - and the 52-week low is -.

What is the dividend yield of Divis Laboratories Ltd.?

The dividend yield of Divis Laboratories Ltd. is 0.35% based on the current market price.

What is the FII and DII holding in Divis Laboratories Ltd.?

Foreign Institutional Investors (FII) hold 20.19%, Domestic Institutional Investors (DII) hold 18.36% and retail/public investors hold 7.35% of Divis Laboratories Ltd. shares.

What sector does Divis Laboratories Ltd. belong to?

Divis Laboratories Ltd. operates in the Healthcare sector. 48.15% of analysts have a Buy or Strong Buy rating on Divis Laboratories Ltd. with a consensus target price of ₹ 7,959.00, implying 7.42% downside from current levels.

What is the beta of Divis Laboratories Ltd.?

The beta of Divis Laboratories Ltd. is 0.56, indicating its price volatility relative to the broader market. Over the past 1 year, Divis Laboratories Ltd. has delivered an absolute return of 40.92%.

What is the RSI of Divis Laboratories Ltd.?

The 14-day Relative Strength Index (RSI) of Divis Laboratories Ltd. is 77.09, placing it in the overbought zone. An RSI above 70 is considered overbought and below 30 is considered oversold.